Sign In
Buy ORMP
$4.07
-0.0500 (-1.21%)
At Close: Jul 31, 2026
ORMP: Second quarter financial results; Strengthens Advisory Board; Positive EoP2 meeting with the FDA
11:10am, Tuesday, 14'th Apr 2020
By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Financial Update Oramed (NASDAQ:ORMP) reported second quarter financial results on 6th April, 2020 and provided a business update
Oramed Patent in Canada Allowed for Oral Delivery of Proteins
11:40am, Tuesday, 07'th Apr 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Can
NVAX, INSG among premarket gainers
01:20pm, Wednesday, 01'st Apr 2020
InflaRx N.V. (NASDAQ:IFRX) +54% with doses of first COVID-19 with IFX-1.Qumu (NASDAQ:QUMU) +39%.Chembio Diagnostics (NASDAQ:CEMI) +26% on launching rapid COVID-19 blood test.Safe-T Group (NASDAQ:SFE
Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
12:40pm, Wednesday, 01'st Apr 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the fo
Does Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Have A Particularly Volatile Share Price?
01:01pm, Monday, 30'th Mar 2020
Anyone researching Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) might want to consider the historical volatility of the...
Analysts Are Bullish on These Healthcare Stocks: Dexcom (DXCM), Stemline Therapeutics (STML)
07:05pm, Monday, 23'rd Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Stemline Therapeutics (STML) with bullish
Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
12:40pm, Thursday, 19'th Mar 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive fee
ORMP: Oramed announces positive results from cohort 2 of Phase 2 trial with ORMD-0801 in T2D patients
10:30am, Wednesday, 11'th Mar 2020
By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Results of the Phase 2b Trial The primary objective of the Phase II study was to explore therapeutic efficacy in patients and mor
Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
02:15pm, Thursday, 27'th Feb 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the p
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fa
Diagnosis: Volatility — Every Coronavirus-Related Stock That Was Halted For Trading Today
12:00am, Thursday, 27'th Feb 2020
Wall Street has been sharply attuned to coronavirus news. In fact, the extreme volatility in the market brought 24 trading halts on Thursday.
Several biotech or pharmaceutical-...
Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
09:05pm, Wednesday, 26'th Feb 2020
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
01:00pm, Wednesday, 26'th Feb 2020
Primary endpoints successfully met
Have Insiders Been Buying Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares This Year?
02:42pm, Wednesday, 12'th Feb 2020
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Oramed to Present at BIO CEO & Investor Conference
01:25pm, Tuesday, 04'th Feb 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nad
